Improving cancer immunotherapy by targeting tumor-induced immune suppression
Identifieur interne : 006A10 ( Main/Exploration ); précédent : 006A09; suivant : 006A11Improving cancer immunotherapy by targeting tumor-induced immune suppression
Auteurs : Trina J. Stewart [Australie] ; Mark J. Smyth [Australie]Source :
- Cancer metastasis reviews [ 0167-7659 ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Cancer, Immunologie.
English descriptors
- KwdEn :
Abstract
The status of a host's immune response influences both the development and progression of a malignancy such that immune responses can have both pro- and anti-tumorigenic effects. Cancer immunotherapy is a form of treatment that aims to improve the ability of a cancer-bearing individual to reject the tumor immunologically. However, antitumor immunity elicited by the host or by immunotherapeutic strategies, can be actively attenuated by mechanisms that limit the strength and/or duration of immune responses, including the presence of immunoregulatory cell types or the production of immunosuppressive factors. As our knowledge of tumor-induced immune suppression increases, it has become obvious that these mechanisms are probably a major barrier to effective therapy. The identification of multiple mechanisms of tumor-induced immune suppression also provides a range of novel targets for new cancer therapies. Given the vital role that a host's immune response is known to play in cancer progression, therapies that target immune suppressive mechanisms have the potential to enhance anticancer immune responses thus leading to better immune surveillance and the limitation of tumor escape. In this review, mechanisms of tumor-associated immune suppression have been divided into four forms that we have designated as (1) regulatory cells; (2) cytokines/chemokines; (3) T cell tolerance/exhaustion and (4) metabolic. We discuss select mechanisms representing each of these forms of immunosuppression that have been shown to aid tumors in evading host immune surveillance and overview therapeutic strategies that have been recently devised to "suppress these suppressors.".
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001E63
- to stream PascalFrancis, to step Curation: 004074
- to stream PascalFrancis, to step Checkpoint: 001993
- to stream Main, to step Merge: 006E44
- to stream Main, to step Curation: 006A10
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Improving cancer immunotherapy by targeting tumor-induced immune suppression</title><author><name sortKey="Stewart, Trina J" sort="Stewart, Trina J" uniqKey="Stewart T" first="Trina J." last="Stewart">Trina J. Stewart</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place</s1><s2>East Melbourne, Victoria, 3002</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>East Melbourne, Victoria, 3002</wicri:noRegion></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place</s1><s2>East Melbourne, Victoria, 3002</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>East Melbourne, Victoria, 3002</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0172964</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0172964 INIST</idno><idno type="RBID">Pascal:11-0172964</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E63</idno><idno type="wicri:Area/PascalFrancis/Curation">004074</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001993</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001993</idno><idno type="wicri:doubleKey">0167-7659:2011:Stewart T:improving:cancer:immunotherapy</idno><idno type="wicri:Area/Main/Merge">006E44</idno><idno type="wicri:Area/Main/Curation">006A10</idno><idno type="wicri:Area/Main/Exploration">006A10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Improving cancer immunotherapy by targeting tumor-induced immune suppression</title><author><name sortKey="Stewart, Trina J" sort="Stewart, Trina J" uniqKey="Stewart T" first="Trina J." last="Stewart">Trina J. Stewart</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place</s1><s2>East Melbourne, Victoria, 3002</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>East Melbourne, Victoria, 3002</wicri:noRegion></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place</s1><s2>East Melbourne, Victoria, 3002</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>East Melbourne, Victoria, 3002</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Cancer metastasis reviews</title><title level="j" type="abbreviated">Cancer metastasis rev.</title><idno type="ISSN">0167-7659</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Cancer metastasis reviews</title><title level="j" type="abbreviated">Cancer metastasis rev.</title><idno type="ISSN">0167-7659</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancer</term><term>Cancerology</term><term>Cytokine</term><term>Immunology</term><term>Immunosuppression</term><term>Immunotherapy</term><term>Malignant tumor</term><term>Myeloid derived suppressor cell</term><term>Targeting</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer</term><term>Traitement</term><term>Ciblage</term><term>Tumeur maligne</term><term>Immunodépression</term><term>Cancérologie</term><term>Immunothérapie</term><term>Immunologie</term><term>Cytokine</term><term>Cellule suppressive d'origine myéloïde</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cancer</term><term>Immunologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The status of a host's immune response influences both the development and progression of a malignancy such that immune responses can have both pro- and anti-tumorigenic effects. Cancer immunotherapy is a form of treatment that aims to improve the ability of a cancer-bearing individual to reject the tumor immunologically. However, antitumor immunity elicited by the host or by immunotherapeutic strategies, can be actively attenuated by mechanisms that limit the strength and/or duration of immune responses, including the presence of immunoregulatory cell types or the production of immunosuppressive factors. As our knowledge of tumor-induced immune suppression increases, it has become obvious that these mechanisms are probably a major barrier to effective therapy. The identification of multiple mechanisms of tumor-induced immune suppression also provides a range of novel targets for new cancer therapies. Given the vital role that a host's immune response is known to play in cancer progression, therapies that target immune suppressive mechanisms have the potential to enhance anticancer immune responses thus leading to better immune surveillance and the limitation of tumor escape. In this review, mechanisms of tumor-associated immune suppression have been divided into four forms that we have designated as (1) regulatory cells; (2) cytokines/chemokines; (3) T cell tolerance/exhaustion and (4) metabolic. We discuss select mechanisms representing each of these forms of immunosuppression that have been shown to aid tumors in evading host immune surveillance and overview therapeutic strategies that have been recently devised to "suppress these suppressors.".</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Stewart, Trina J" sort="Stewart, Trina J" uniqKey="Stewart T" first="Trina J." last="Stewart">Trina J. Stewart</name></noRegion><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006A10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006A10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0172964
|texte= Improving cancer immunotherapy by targeting tumor-induced immune suppression
}}
| This area was generated with Dilib version V0.6.33. |  |